Integrating serum biomarkers into prediction models for biochemical recurrence following radical prostatectomy
| Autor: | Shirin Moghaddam, Kristin Austlid Taskén, Helmut Klocker, R. William G. Watson, Amanda O'Neill, Viktor Berge, Lisa N. Murphy, Anne-Marie Reilly, Richard E. Power, Laura Gorman, K.J. O’Malley, T. Brendan Murphy, Amirhossein Jalali, Thomas H. Lynch, Vivi-Ann Solhaug, Áine Heffernan |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
Biochemical recurrence
Oncology Cancer Research medicine.medical_specialty model evaluation medicine.medical_treatment 030232 urology & nephrology Overfitting Article 03 medical and health sciences Prostate cancer 0302 clinical medicine Internal medicine medicine biochemical recurrence cytokine RC254-282 Proportional hazards model Prostatectomy business.industry Neoplasms. Tumors. Oncology. Including cancer and carcinogens prediction models Stepwise regression medicine.disease calibration prostate cancer 3. Good health 030220 oncology & carcinogenesis Cox model Biomarker (medicine) business Predictive modelling discrimination |
| Zdroj: | Cancers Cancers, Vol 13, Iss 4162, p 4162 (2021) Volume 13 Issue 16 |
| ISSN: | 2072-6694 |
| Popis: | Simple Summary Treatment decisions represent a significant dilemma for patients diagnosed with prostate cancer. The prediction of early treatment failure would inform appropriate decision making and allow the clinician and patient to consider appropriate primary treatments and adjuvant therapies. We have developed and validated a serum biomarker-based model for predicting risk of biochemical reoccurrence in prostate cancer after radical prostatectomy. This study shows that the pre-operative biomarker PEDF can improve the accuracy of the clinical factors to predict risk of biochemical reoccurrence. PEDF has anti-inflammatory effects impacting on cytokine production. This non-invasive tool can be employed prior to treatment and demonstrates significant benefit over current clinical practice, impacting on patients’ outcomes and quality of life. Abstract This study undertook to predict biochemical recurrence (BCR) in prostate cancer patients after radical prostatectomy using serum biomarkers and clinical features. Three radical prostatectomy cohorts were used to build and validate a model of clinical variables and serum biomarkers to predict BCR. The Cox proportional hazard model with stepwise selection technique was used to develop the model. Model evaluation was quantified by the AUC, calibration, and decision curve analysis. Cross-validation techniques were used to prevent overfitting in the Irish training cohort, and the Austrian and Norwegian independent cohorts were used as validation cohorts. The integration of serum biomarkers with the clinical variables (AUC = 0.695) improved significantly the predictive ability of BCR compared to the clinical variables (AUC = 0.604) or biomarkers alone (AUC = 0.573). This model was well calibrated and demonstrated a significant improvement in the predictive ability in the Austrian and Norwegian validation cohorts (AUC of 0.724 and 0.606), compared to the clinical model (AUC of 0.665 and 0.511). This study shows that the pre-operative biomarker PEDF can improve the accuracy of the clinical factors to predict BCR. This model can be employed prior to treatment and could improve clinical decision making, impacting on patients’ outcomes and quality of life. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|